KoBioLabs, a company specializing in the development of innovative biopharmaceuticals, announced on November 19 that it had participated in BIO-Europe 2026, held in Cologne, Germany, from November 9 to 11 (local time), where it confirmed strong interest from several global pharmaceutical companies in its mDDS (drug delivery system) platform.


KoBioLabs Introduces Its Drug Delivery Technology at 'BIO-Europe 2026' View original image

BIO-Europe is Europe's largest pharmaceutical and biotechnology partnering event. According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, more than 3,100 companies from 65 countries participated in this year's event. CEO Lee Hanseung attended in person and held one-on-one meetings with global pharmaceutical and biotechnology companies, introducing the platform's research and development progress and the technological competitiveness of its drug delivery technology.


mDDS is a next-generation drug delivery technology based on synthetic biology that selectively delivers drugs to cancer tissue. It maximizes drug delivery efficiency at tumor sites by using drug carriers that can be selectively expressed only in the microenvironment inside solid tumors. Since its founding in 2014, the company has been developing mDDS as a next-generation growth engine, drawing on its accumulated experience in bioengineering and global drug development.


According to the company, several global pharmaceutical companies that took part in the meetings showed strong interest in mDDS. The company believes global pharmaceutical companies were drawn to the technology because it offers a new drug delivery method that could address both systemic toxicity, a longstanding challenge in cancer drug development, and the short half-life of drugs. KoBioLabs plans to continue developing the areas of interest identified in its meetings with global pharmaceutical companies through joint research, technology transfers and other initiatives.



"We will do our utmost to turn this interest into tangible global partnership outcomes by sharing additional data with global pharmaceutical companies and holding close follow-up discussions," said Jeon Heekyung, director of business development at KoBioLabs.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing